COX-2 and colon cancer: Potential targets for chemoprevention

Journal of Cellular Biochemistry

Volumn 77, Issue SUPPL. 34, 2000, Pages 97-102

  Fournier, David B ^a   Gordon, Gary B ^a  

^a PFIZER INC   (United States)

Author keywords

Arachidonic acid; Cancer prevention; Cyclooxygenase; NSAID; Prostaglandin

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

CANCER PREVENTION; COLON CANCER; COLON CARCINOGENESIS; DISEASE ASSOCIATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ADENOMATOUS POLYP; ANIMAL; COLON TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALIA;

ADENOMATOUS POLYPS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 0033655574     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(2000)77:34+<97::AID-JCB16>3.0.CO;2-Z     Document Type: Review

References (25)

1. American Cancer Society. 1994. Cancer facts and figures. 1994 Atlanta, Georgia.
2. Balch CM, Dougherty PA, Cloud GA, Tilden AB. 1984. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95:71-77.
3. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, Kinzler KW. 1996. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17:1757-1760.
4. Bhana D, Hillier K, Karim SMM. 1971. Vasoactive substances in Kaposi's sarcoma. Cancer 27:233-237.
5. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J. 1997. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 32:126-130.
6. Bockmann RS, Meyers WPL. 1977. Osteoporism of human breast cancer. Cancer Res 5:431-450.
7. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM. 1996. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560.
8. Campbell WB, Halushka PV. 1996. Lipid-derived autacoids. Eicosanoids and platelet-activating factor. In: Hardman WE, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 9th edition. New York: McGraw-Hill, p 601-616.
9. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. 1998. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681-686.
10. Cummings KB, Robertson RP. 1977. Prostaglandins: Increased production by renal cell carcinoma. J Urol 118: 720-723.
11. Denizot Y, Najid A, Rigaud M. 1993. Effects of eicosanoid metabolism inhibitors on growth of a human gastric tumour cell line (HGT). Cancer Lett 73:65-71.
12. DuBois RN, Radhika A, Reddy BS, Entingh AJ. 1996. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110:1259-1262.
13. Earnest DL, Hixson LJ, Alberts DS. 1992. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl 161:156-166.
14. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188.
15. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
16. 2α in serum of bronchial carcinoma patients. In: Samulesson B, Paoletti R, editors. Advances in prostaglandin and thromboxane research. New York: Raven Press, p 585-586.
17. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316.
18. Giardiello FM, Offerhaus GJ, DuBois RN. 1995a. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 31A:1071-1076.
19. Jacoby RF, Cole CE, Seibert K, Kelloff G, Lubet RA. 1998. The specific cyclooxygenase-2 inhibitor, celecoxib, causes adenoma regression in the Apc mutant Min mouse model. AACR Latebreaking Research Section.
20. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, Kelloff GJ, Verma A, Moser AR, Dove WF. 1996. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710-714.
21. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. 1995. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556-2559.
22. Kawamori T, Rao CV, Seibert K, Reddy BS. 1998. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412.
23. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639.
24. Lupulescu A. 1996. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot and Essent Fatty Acids 54:83-94.
25. Masferrer JL, Zweifel BS, Manning FT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert KS. 1994. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232.